Background: Frontal fibrosing alopecia (FFA) is a primary lymphocytic scarring alopecia occurring mainly in postmenopausal women. A range of facial lesions have been described in FFA, such as lichen planus (LP) pigmentosus, red dots, facial papules, and perifollicular and diffuse erythema. These lesions can be the first sign of FFA. LP pigmentosus is a rare variant of LP. The first description of LP pigmentosus associated with FFA (in 2012) reported 22 cases of LP pigmentosus among 44 cases of FFA affecting South African patients. Methods: We reviewed 16 FFA patients with LP pigmentosus and the histopathological findings of the biopsy of LP pigmentosus in 9 patients. Results: Most patients had intermediate skin phototypes (III-IV; n = 10; 62%). The age at onset of LP pigmentosus ranged from 30 to 60 years. The most common histopathological findings were epidermal atrophy, basal cell degeneration, interfollicular inflammatory infiltrate and melanophages, and perifollicular changes. Other findings not previously described in LP pigmentosus were inflammation and interface changes on sweat duct epithelia (acrosyringium and superior dermal duct), and lichenoid perisebaceitis. Conclusions: Histology of our cases confirmed previous findings and showed a high incidence of perifollicular involvement with occasional changes affecting sebaceous and sweat glands.

1.
Lacarrubba F, Micali G, Tosti A: Absence of vellus hair in the hairline: a videodermatoscopic feature of frontal fibrosing alopecia. Br J Dermatol 2013;169:473-474.
2.
Rácz E, Gho C, Moorman PW, Noordhoek Hegt V, Neumann HA: Treatment of frontal fibrosing alopecia and lichen planopilaris: a systematic review. J Eur Acad Dermatol Venereol 2013;27:1461-1470.
3.
Miteva M, Whiting D, Harries M, Bernardes A, Tosti A: Frontal fibrosing alopecia in black patients. Br J Dermatol 2012;167:208-210.
4.
Camacho Martínez F, García-Hernández MJ, Mazuecos Blanca J: Postmenopausal frontal fibrosing alopecia. Br J Dermatol 1999;140:1181-1182.
5.
Dlova NC: Frontal fibrosing alopecia and lichen planus pigmentosus: is there a link? Br J Dermatol 2013;168:439-442.
6.
Kanwar AJ, Dogra S, Handa S, Parsad D, Radotra BD: A study of 124 Indian patients with lichen planus pigmentosus. Clin Exp Dermatol 2003;28:481-485.
7.
Al-Mutairi N, El-Khalawany M: Clinicopathological characteristics of lichen planus pigmentosus and its response to tacrolimus ointment: an open label, non-randomized, prospective study. J Eur Acad Dermatol Venereol 2010;24:535-540.
8.
Rao R, Sarda A, Khanna R, Balachandran C: Coexistence of frontal fibrosing alopecia with lichen planus pigmentosus. Int J Dermatol 2014;53:622-624.
9.
Berliner JG, McCalmont TH, Price VH, Berger TG: Frontal fibrosing alopecia and lichen planus pigmentosus. J Am Acad Dermatol 2014;71:e26-e27.
10.
Bhutani LK, Bedi TR, Pandhi RK, Nayak NC: Lichen planus pigmentosus. Dermatologica 1974;149:43-50.
11.
Abbas O, Chedraoui A, Ghosn S: Frontal fibrosing alopecia presenting with components of Piccardi-Lassueur-Graham-Little syndrome. J Am Acad Dermatol 2007;57(2 Suppl):S15-S18.
12.
López-Pestaña A, Tuneu A, Lobo C, Ormaechea N, Zubizarreta J, Vildosola S, et al: Facial lesions in frontal fibrosing alopecia (FFA): clinicopathological features in a series of 12 cases. J Am Acad Dermatol 2015;73:987.e1-e6.
13.
Pirmez R, Donati A, Valente NS, Sodré CT, Tosti A: Glabellar red dots in frontal fibrosing alopecia: a further clinical sign of vellus follicle involvement. Br J Dermatol 2014;170:745-746.
14.
Enhamre A, Lagerholm B: Acrosyringeal lichen planus. Acta Derm Venereol 1987;67:346-350.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.